<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191027045254N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-11-27</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Effectiveness of Enhanced Recovery After Surgery (ERAS)</public_title>
      <acronym></acronym>
      <scientific_title>Effects of Enhanced Recovery After Surgery (ERAS) Program Implementation on Hospital Stay Duration and Costs in Children underwent Colostomy Closure Surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-01-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>160</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51658</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Using a table of random numbers, the researcher determines the direction to read the numbers and touches one of the numbers with his eyes closed. When each item enters the study, the researcher moves in a predetermined direction. Even numbers will be assigned to the intervention group and odd numbers to the control group, Blinding description: In this study, data analyst is blind.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Colostomy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: ERAS protocol is performed in the patients of the intervention group. Implementation of the ERAS protocol includes the following: A. Preoperative: Intestinal prep only by oral Metronidazole, administration of clear liquids up to 2 hours before surgery, carbohydrate load as a serving of apple juice at two hours before surgery, Gabapentin loading dose of 15 mg/kg body weight three hours before surgery. B. Intraoperative: prophylactic antibiotic before surgical incision, prefer minimally invasive methods, not using unnecessary drains and tubes such as nasogastric tubes, maintaining normal temperature during surgery and preventing hypothermia, local anesthesia and regional blocks if effective, reduction and elimination of opioids, restriction of crystalloid intravenous fluids to 3-4 ml/kg/h. C. Postoperative: immediate limited mobility after surgery, limited clear fluid intake immediately after surgery as tolerated followed by normal diet, minimizing intravenous fluids and no bolus serum administration, avoiding opioids to relieve pain and administration of Acetaminophen 10 mg/ kg every 6 hours (maximum 650 mg every 6 hours), Ketorolac 0.5 mg/kg every 6 hours (maximum 30 mg every 6 hours), and Gabapentin 10 mg/kg every 8 hours (maximum 600 mg each 6 hours), control of nausea and vomiting by intravenous Ondansetron 0.1 mg/kg every 8 hours, aggressive and serious respiratory physiotherapy, and administration of intestinal motility drugs. Intervention 2: Control group: According to the routine of the surgical ward, patients will be NPO (nothing by mouth) 12 hours before surgery, receive intravenous antibiotics before surgery, and in some cases, mechanical preparation of the intestine with serial enema is applied. After surgery, patients will receive opioids in case of pain. Also, they would be NPO for up to 72 hours after surgery, followed by the normal diet, if the fluid diet is tolerated.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Reza ُShojaeian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>3rd unit, No. 109, Farhad 15 St., Malekabad Blvd.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>٩١٧٧٨٩٧١۵٧</zip>
        <telephone>+98 51 3766 5574</telephone>
        <email>shojaeianr@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Reza ُShojaeian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>3rd unit, No. 109, Farhad 15 St., Malekabad Blvd.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>٩١٧٧٨٩٧١۵٧</zip>
        <telephone>+98 51 3766 5574</telephone>
        <email>shojaeianr@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 28 days to 14 years
History of a prior surgery resulted in a colostomy
Being a candidate of colostomy closure surgery</inclusion_criteria>
      <agemin>28 days</agemin>
      <agemax>14 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Underlying disease that leads to tissue repair impairments  (such as sever malnutrition or connective tissue disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K94.00</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Colostomy complication, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: ERAS protocol is performed in the patients of the intervention group. Implementation of the ERAS protocol includes the following: A. Preoperative: Intestinal prep only by oral Metronidazole, administration of clear liquids up to 2 hours before surgery, carbohydrate load as a serving of apple juice at two hours before surgery, Gabapentin loading dose of 15 mg/kg body weight three hours before surgery. B. Intraoperative: prophylactic antibiotic before surgical incision, prefer minimally invasive methods, not using unnecessary drains and tubes such as nasogastric tubes, maintaining normal temperature during surgery and preventing hypothermia, local anesthesia and regional blocks if effective, reduction and elimination of opioids, restriction of crystalloid intravenous fluids to 3-4 ml/kg/h. C. Postoperative: immediate limited mobility after surgery, limited clear fluid intake immediately after surgery as tolerated followed by normal diet, minimizing intravenous fluids and no bolus serum administration, avoiding opioids to relieve pain and administration of Acetaminophen 10 mg/ kg every 6 hours (maximum 650 mg every 6 hours), Ketorolac 0.5 mg/kg every 6 hours (maximum 30 mg every 6 hours), and Gabapentin 10 mg/kg every 8 hours (maximum 600 mg each 6 hours), control of nausea and vomiting by intravenous Ondansetron 0.1 mg/kg every 8 hours, aggressive and serious respiratory physiotherapy, and administration of intestinal motility drugs.</i_keyword>
      <i_keyword>Control group: According to the routine of the surgical ward, patients will be NPO (nothing by mouth) 12 hours before surgery, receive intravenous antibiotics before surgery, and in some cases, mechanical preparation of the intestine with serial enema is applied. After surgery, patients will receive opioids in case of pain. Also, they would be NPO for up to 72 hours after surgery, followed by the normal diet, if the fluid diet is tolerated.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Duration of hospitalization: The total number of hospitalization days as the days between the date of discharge and date of hospitalization. Timepoint: Once after patients discharge. Method of measurement: Based on the date of admission and date of discharge, recorded in the hospital information system.</prim_outcome>
      <prim_outcome>Time interval to tolerate oral intake: time interval between end of surgery and first oral feeding followed by no vomiting in hours. Timepoint: Once durnig hospital stay after oral intake tolerance. Method of measurement: Interval between the time of the first tolerated feeding recorded by the patient's nurse and the end time of the operation recorded in the operation report sheet in hours.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-05-11</approval_date>
        <contact_name>Ethics Committee of Medical Faculty, Mashhad University of Medical Sciences</contact_name>
        <contact_address>Faculty of Medicine, Mashhad University of Medical Sciences, Azadi Square Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
